Fidia S.p.A. (BIT:FDA)
0.0529
-0.0021 (-3.82%)
At close: Mar 6, 2026
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.04
Revenue / Employee
150.93K
Employees
140
Market Cap
788.21K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| OSAI Automation System | 41.92M |
| Clabo | 58.10M |
| Marzocchi Pompe | 37.06M |
| Esautomotion | 28.29M |
| ErreDue | 17.78M |
| Valtecne | 34.06M |
| ILPRA | 80.39M |
| SIT S.p.A. | 314.71M |
Fidia News
- 7 hours ago - What's Going On With Iovance Biotherapeutics Stock On Friday? - Benzinga
- 8 hours ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 10 hours ago - Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet - Nasdaq
- 11 hours ago - Halozyme Says J&J Wins FDA Approval For Tecvayli, Darzalex Faspro Combo In Multiple Myeloma - Nasdaq
- 12 hours ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Benzinga
- 15 hours ago - FDA Roundup: First-Line Hernexeos, Weekly Yuviwel, Expanded Palynziq & Sogroya Indications - Nasdaq
- 23 hours ago - Outlook Therapeutics Updates FDA Path For ONS-5010 Following Type A Meeting - Nasdaq
- 1 day ago - uniQure (QURE) Faces FDA Demand for Phase 3 Trial for Huntington's Drug - GuruFocus